Aesica appoints Chris Gowland to the Board

pharmafile | July 30, 2013 | Appointment | Manufacturing and Production, Research and Development, Sales and Marketing Aesica, Chris Gowland 

Contract development and manufacturing organisation Aesica has appointed Chris Gowland to the newly formed position of chief operating officer.

As COO, Gowland has overall responsibility for all operating strategy. He will lead international operational delivery and his remit encompasses the setting of operational standards and driving improvements across the firm’s manufacturing capabilities in API and formulated products.

Gowland is now responsible for operational performance and general management of all Aesica manufacturing sites including Queenborough and Cramlington in the UK, Monheim and Zwickau in Germany and Pianezza in Italy.

Under the new structure, Steve Barker, and Jarrett Palmer, operations directors for the API and Formulated Products business units respectively, will report directly to the COO.
 

Gowland said: “I am delighted to have the opportunity to lead a manufacturing structure in which I am responsible for driving highly efficient operational delivery and the highest standards of operational excellence across Aesica internationally.”

Related Content

screen_shot_2014-03-18_at_08

Pharma manufacturing news in brief

 Bayer says it plans to invest more than €500 million to establish additional manufacturing capacity …

Aesica image

Aesica gets bigger in pre-filled syringes

UK contract development and manufacturing organisation Aesica is expanding production capacity for pre-filled syringes at …

Aesica image

Aesica forges alliance with UK university on API synthesis

UK contract manufacturing organisation (CMO) Aesica has teamed up with the University of Nottingham to …

Latest content